Related Experiment Video

Updated: May 8, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum

Oliver Schnell1, Arnav Agarwal2,3,4, Michel Azizi5,6

  • 1Forschergruppe Diabetes E. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg, Germany. oliver.schnell@lrz.uni-muenchen.de.

Cardiovascular Diabetology
|May 7, 2026
PubMed

Insights

The 2025 Cardiovascular Outcome Trial Summit highlighted new therapies for cardiovascular, kidney, and metabolic diseases. Key discussions included combination treatments, inflammatory insights, and policy updates for the CKM continuum.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Metabolic Disorders
  • Pharmacology

Background:

  • The 11th Cardiovascular Outcome Trial (CVOT) Summit convened experts to discuss emerging therapies for the cardiovascular-kidney-metabolic (CKM) continuum.
  • The summit focused on recent outcome trials and advancements in treating complex interconnected diseases.

Purpose of the Study:

  • To summarize key developments presented at the 2025 CVOT Summit.
  • To highlight pioneering clinical trials, combination therapies, and new insights into CKM syndrome.
  • To review recent guideline and policy developments relevant to CKM disease management.

Main Methods:

  • The report synthesizes information from the multidisciplinary 11th CVOT Summit held virtually on November 20-21, 2025.
  • It covers discussions on clinical trials, expert opinions from various medical specialties, and policy updates.
  • Advances in medical technology, including continuous monitoring, were also presented.

Main Results:

  • Pioneering trials included combination therapy with finerenone and empagliflozin (CONFIDENCE) and oral glucagon-like peptide-1 (GLP-1) receptor agonists (orforglipron).
  • The first head-to-head CVOT (SURPASS-CVOT) and the role of aldosterone synthase inhibitors (baxdrostat) were discussed.
  • New insights into the inflammatory component of CKM syndrome and advances in metabolic disorder treatments were presented.

Conclusions:

  • The 2025 CVOT Summit underscored significant progress in pharmacological therapies and understanding of the CKM continuum.
  • Combination therapies, inflammatory mechanisms, and technological advancements are crucial for future treatment strategies.
  • The 12th CVOT Summit is scheduled for November 19-20, 2026.
Keywords:
Aldosterone synthase inhibitorsCGMDiabetesHeart failureIncretin mimeticsMASLDNonsteroidal mineralcorticoid receptor antagonistsObesitySGLT2 inhibitorSoluble guanylate cyclase stimulators

More Related Videos

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...